C7938
2-氯-N6-环戊基腺苷
adenosine receptor agonist
别名:
CCPA
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C15H20ClN5O4
化学文摘社编号:
分子量:
369.80
NACRES:
NA.51
PubChem Substance ID:
UNSPSC Code:
41106305
MDL number:
Assay:
≥98% (TLC)
Form:
powder
Solubility:
methanol: 19.60-20.40 mg/mL, clear, colorless to faintly yellow
Storage temp.:
2-8°C
InChI
1S/C15H20ClN5O4/c16-15-19-12(18-7-3-1-2-4-7)9-13(20-15)21(6-17-9)14-11(24)10(23)8(5-22)25-14/h6-8,10-11,14,22-24H,1-5H2,(H,18,19,20)/t8-,10-,11-,14-/m1/s1
SMILES string
OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n2cnc3c(NC4CCCC4)nc(Cl)nc23
InChI key
XSMYYYQVWPZWIZ-IDTAVKCVSA-N
assay
≥98% (TLC)
form
powder
solubility
methanol: 19.60-20.40 mg/mL, clear, colorless to faintly yellow
storage temp.
2-8°C
Quality Level
Gene Information
human ... ADORA1(134), ADORA2A(135), ADORA2B(136), ADORA3(140)
rat ... Adora1(29290), Adora2a(25369), Adora3(25370)
Application
2-氯-N6-环戊基腺苷（CCPA）是一种具有高选择性的A1腺苷受体激动剂。CCPA通常与其他腺苷受体激动剂和拮抗剂一起使用，以平衡A(1)、A(2A)和A(3)受体的功能。这些药物包括DPCPX（A(1) 受体拮抗剂）、4-(2-[7-氨基-2-(2-呋喃基)[1,2,4]三唑[2,3-α][1,3,5]三嗪-5-基氨基]乙基)苯酚（A(2A)受体拮抗剂）和4-[2-[[6-氨基-9-(N-乙基-β-D-核呋喃核糖酰胺基)-9H-嘌呤-2-基]氨基]乙基]苯丙酸盐酸盐（A(2A) 受体激动剂）和Cl-IB-MECA（A(3)受体激动剂）。
Biochem/physiol Actions
具有高选择性的A1腺苷受体激动剂：据报道，A1受体的选择性是A2受体的10,000倍。
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
Ellen V Langemeijer et al.
Purinergic signalling, 9(1), 91-100 (2012-10-12)
The concept of functional selectivity offers great potential for the development of drugs that selectively activate a specific intracellular signaling pathway. During the last few years, it has become possible to systematically analyse compound libraries on G protein-coupled receptors (GPCRs)
Luca Soattin et al.
Frontiers in physiology, 11, 493-493 (2020-07-01)
Adenosine leads to atrial action potential (AP) shortening through activation of adenosine 1 receptors (A1-R) and subsequent opening of G-protein-coupled inwardly rectifying K+ channels. Extracellular production of adenosine is drastically increased during stress and ischemia. The aim of this study
Romeo Romagnoli et al.
Journal of medicinal chemistry, 51(18), 5875-5879 (2008-08-30)
The synthesis and evaluation of a series of 2-amino-3-(4-chlorobenzoyl)-4-[4-(alkyl/aryl)piperazin-yl]thiophene derivatives as allosteric enhancers of the A 1-adenosine receptor are described. The nature of substituents on the phenyl ring tethered to the piperazine seem to exert a fundamental influence on the
Mary Clare Luca et al.
Clinical hemorheology and microcirculation, 49(1-4), 287-293 (2012-01-05)
Despite decades of research and thousands of experimental publications, acute preconditioning strategies have yet to be implemented in clinical practice. While some have attributed this to a failure of the experimental studies to mimic the clinical environment, others have suggested
N L D Smith et al.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 20(8), O480-O488 (2013-11-28)
Chronic cavitary pulmonary aspergillosis (CCPA) is a progressive lung condition with a 10-30% annual mortality. Although overtly immunocompetent, some immunogenetic defect in patients is likely. To investigate a possible immunogenetic defect in CCPA, we analysed biologically plausible candidate genes in
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持